Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RORA_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RORA_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RORA_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RORA_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RORA_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RORA_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RORA_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RORA_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RORA_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RORA_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RORA_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00454445 | Cervix | CC | fat cell differentiation | 53/2311 | 229/18723 | 3.72e-06 | 9.75e-05 | 53 |
GO:00346129 | Cervix | CC | response to tumor necrosis factor | 55/2311 | 253/18723 | 1.75e-05 | 3.32e-04 | 55 |
GO:00713569 | Cervix | CC | cellular response to tumor necrosis factor | 51/2311 | 229/18723 | 1.75e-05 | 3.32e-04 | 51 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00076238 | Cervix | CC | circadian rhythm | 46/2311 | 210/18723 | 6.76e-05 | 9.60e-04 | 46 |
GO:000166610 | Cervix | CC | response to hypoxia | 61/2311 | 307/18723 | 1.04e-04 | 1.34e-03 | 61 |
GO:007048210 | Cervix | CC | response to oxygen levels | 67/2311 | 347/18723 | 1.21e-04 | 1.51e-03 | 67 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:003629310 | Cervix | CC | response to decreased oxygen levels | 62/2311 | 322/18723 | 2.29e-04 | 2.57e-03 | 62 |
GO:00302173 | Cervix | CC | T cell differentiation | 51/2311 | 257/18723 | 3.81e-04 | 3.89e-03 | 51 |
GO:00714539 | Cervix | CC | cellular response to oxygen levels | 38/2311 | 177/18723 | 4.23e-04 | 4.27e-03 | 38 |
GO:00196939 | Cervix | CC | ribose phosphate metabolic process | 72/2311 | 396/18723 | 4.49e-04 | 4.48e-03 | 72 |
GO:00092599 | Cervix | CC | ribonucleotide metabolic process | 70/2311 | 385/18723 | 5.35e-04 | 5.18e-03 | 70 |
GO:00362949 | Cervix | CC | cellular response to decreased oxygen levels | 35/2311 | 161/18723 | 5.49e-04 | 5.29e-03 | 35 |
GO:19031314 | Cervix | CC | mononuclear cell differentiation | 76/2311 | 426/18723 | 5.66e-04 | 5.42e-03 | 76 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RORA | SNV | Missense_Mutation | | c.95G>C | p.Arg32Thr | p.R32T | P35398 | protein_coding | tolerated_low_confidence(0.07) | benign(0.011) | TCGA-18-3416-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RORA | SNV | Missense_Mutation | novel | c.68N>C | p.Gly23Ala | p.G23A | P35398 | protein_coding | deleterious_low_confidence(0) | benign(0.023) | TCGA-43-A474-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR |
RORA | SNV | Missense_Mutation | novel | c.895C>A | p.Pro299Thr | p.P299T | P35398 | protein_coding | deleterious(0.03) | benign(0.327) | TCGA-46-3768-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | SD |
RORA | SNV | Missense_Mutation | novel | c.1544G>C | p.Gly515Ala | p.G515A | P35398 | protein_coding | tolerated(0.53) | benign(0.033) | TCGA-56-1622-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
RORA | SNV | Missense_Mutation | novel | c.832N>A | p.Cys278Ser | p.C278S | P35398 | protein_coding | tolerated(0.33) | possibly_damaging(0.497) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RORA | SNV | Missense_Mutation | novel | c.977A>G | p.Glu326Gly | p.E326G | P35398 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-90-7964-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RORA | SNV | Missense_Mutation | novel | c.1663G>A | p.Asp555Asn | p.D555N | P35398 | protein_coding | deleterious_low_confidence(0) | benign(0.411) | TCGA-O2-A52Q-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
RORA | SNV | Missense_Mutation | novel | c.1199N>A | p.Arg400Lys | p.R400K | P35398 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-CR-6472-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | paclitaxel | SD |
RORA | SNV | Missense_Mutation | novel | c.1634C>G | p.Thr545Ser | p.T545S | P35398 | protein_coding | tolerated(1) | benign(0.028) | TCGA-F7-A50J-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
RORA | SNV | Missense_Mutation | novel | c.291N>A | p.Met97Ile | p.M97I | P35398 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-F7-A623-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | | interferon beta-1a | | 31649263 |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 381118853 | | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 135651223 | T091317 | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 135651457 | CHOLESTEROL | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | | citalopram | CITALOPRAM | 19846067 |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 135651458 | | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 178100434 | | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | agonist | 310264687 | | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | | T091317 | T091317 | |
6095 | RORA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR, KINASE | | US9598431, 3 | | |